Stock Events

Stock Events

Telix Pharmaceuticals 

$11.94
132
+$0.20+1.7% Friday 20:00
-$0.14-1.14%Friday 23:44After hours

Statistics

Day High
11.95
Day Low
11.94
52W High
12.48
52W Low
6.28
Volume
6,513
Avg. Volume
-
Mkt Cap
4.04B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 6
$0.04
Jan 6
$0.04
Oct 5
$0.04
Jul 5
$0.04
Apr 5
$0.04
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19AugExpected
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.01
0.04
0.09
0.13
Expected EPS
0.044699
Actual EPS
0.1074

Financials

-0.89%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
803.79MRevenue
-7.13MNet Income

Analyst Ratings

21.33Average Price Target
The highest estimate is 22.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TLX. It's not an investment recommendation.
CSL
28
CSL.AU
WiseTech Global Limited
18
WTC.AU
NVIDIA
17
NVDA
Microsoft
16
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alternative Access First Priority CLO Bond
AAA
Mkt Cap0
Advanced Accelerator Applications, a Novartis company, competes in the radiopharmaceuticals market for diagnostic and therapeutic applications, similar to Telix's focus area.
ClearPoint Neuro
CLPT
Mkt Cap474.34M
ClearPoint Neuro, Inc. specializes in precision delivery of therapeutics to the brain, competing in the neuro-oncology segment where Telix also operates.
Novartis
NVS
Mkt Cap292.35B
Novartis AG, through its acquisitions and internal development, competes across a broad range of therapeutic areas including those targeted by Telix's radiopharmaceuticals.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies Inc. has a diverse portfolio that includes products competing in the oncology and radiopharmaceutical sectors.
Protagonist Therapeutics
PTGX
Mkt Cap9.34B
Protagonist Therapeutics, Inc. is involved in the development of peptide-based therapeutics, competing in the innovative treatment space including cancer, where Telix is also active.
Dr. Reddy`s Laboratories
RDY
Mkt Cap10.15B
Dr. Reddy’s Laboratories Ltd. manufactures and markets a wide range of pharmaceuticals globally, including generic versions of drugs that compete with Telix's offerings.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company operates in the oncology space with a broad portfolio of drugs that compete with Telix Pharmaceuticals in the cancer treatment market.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company has a strong presence in oncology and radiopharmaceuticals, directly competing with Telix in several therapeutic areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a global pharmaceutical giant with a diverse portfolio, including oncology and radiopharmaceuticals, making it a competitor in multiple areas relevant to Telix.

About

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Show more...
CEO
Christian Behrenbruch
Employees
1184
Country
Australia
ISIN
US87961M1053
WKN
000A40FCQ

Listings

MX
MX
TLX1N.MX
AU
AU
TLX.AU
F
DE
T3X0.F
OTC Link
US
TLPPF

0 Comments

Share your thoughts

FAQ

What is Telix Pharmaceuticals stock price today?▼
The current price of TLX is $11.94 USD — it has increased by +1.7% in the past 24 hours. Watch Telix Pharmaceuticals stock price performance more closely on the chart.
What is Telix Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Telix Pharmaceuticals stocks are traded under the ticker TLX.
Is Telix Pharmaceuticals stock price growing?▼
TLX stock has risen by +5.76% compared to the previous week, the month change is a +12.22% rise, over the last year Telix Pharmaceuticals has showed a +31.79% increase.
What is Telix Pharmaceuticals market cap?▼
Today Telix Pharmaceuticals has the market capitalization of 4.04B
When is the next Telix Pharmaceuticals earnings date?▼
Telix Pharmaceuticals is going to release the next earnings report on February 19, 2027.
What were Telix Pharmaceuticals earnings last quarter?▼
TLX earnings for the last quarter are 0.11 USD per share, whereas the estimation was 0.04 USD resulting in a +140.27% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Telix Pharmaceuticals revenue for the last year?▼
Telix Pharmaceuticals revenue for the last year amounts to 803.79M USD.
What is Telix Pharmaceuticals net income for the last year?▼
TLX net income for the last year is -7.13M USD.
Does Telix Pharmaceuticals pay dividends?▼
Yes, TLX dividends are paid quarterly. The last dividend per share was 0.04 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Telix Pharmaceuticals have?▼
As of September 06, 2026, the company has 1,184 employees.
In which sector is Telix Pharmaceuticals located?▼
Telix Pharmaceuticals operates in the Health & Wellness sector.
When did Telix Pharmaceuticals complete a stock split?▼
Telix Pharmaceuticals has not had any recent stock splits.
Where is Telix Pharmaceuticals headquartered?▼
Telix Pharmaceuticals is headquartered in North Melbourne, Australia.